Inflammatory Skin Research Program
Queen Skin
Herbal-Based Therapeutic
for Inflammatory Skin Conditions
Queen Skin is AriaNova Bio's herbal-based research program for inflammatory skin conditions, including psoriasis and eczema. Formulated from natural herbal compounds, it is being studied for its potential to support skin barrier function and modulate inflammatory responses.
The Burden of Inflammatory Skin Disease
Selected U.S. and global indicators illustrating the prevalence of psoriasis and eczema — two of the most common chronic inflammatory skin conditions.
People living with psoriasis in the United States, reported in 2025
Estimated people worldwide affected by psoriasis or psoriatic arthritis, reported by NPF in 2024
Estimated global prevalence of psoriatic arthritis among people with psoriasis, published in 2024
Estimated global economic burden of psoriasis in 2021
Mean annual cost of first-line biologic treatment for U.S. plaque psoriasis patients in 2021, reported in 2025
People with psoriasis who experience plaque psoriasis, reviewed in 2026
Calculated estimate of Americans with diagnosed eczema in 2024, based on CDC/NCHS Data Briefs 545 and 546 and U.S. Census 2024
Calculated estimate of the share of the U.S. population with diagnosed eczema in 2024, based on CDC/NCHS Data Briefs 545 and 546 and U.S. Census 2024
Mean annual all-cause healthcare costs among U.S. patients with atopic dermatitis initiating systemic therapy, reported in 2025
Estimated people worldwide living with atopic dermatitis, published in 2024
Estimated children aged 0–14 years worldwide living with atopic dermatitis in 2021, published in 2025
Mean annual gross healthcare charges among U.S. patients with moderate-to-severe atopic dermatitis in the severe-itch/severe-lesion subgroup, reported in 2025
Sources
- [1]National Psoriasis Foundation. Impact Report 2025. psoriasis.org/impact-report-2025
- [2]National Psoriasis Foundation. National Psoriasis Foundation Sets the Course for a Cure. 2024. psoriasis.org/national-psoriasis-foundation-sets-the-course-for-cure
- [3]Global and Regional Epidemiology of Psoriatic Arthritis in Patients with Psoriasis (2024). pubmed.ncbi.nlm.nih.gov/38493674
- [4]Wei J, et al. Global Burden of Psoriasis from 1990 to 2021 and Potential Factors: A Systematic Analysis. Journal of Investigative Dermatology. 2026. doi.org/10.1016/j.jid.2025.08.038
- [5]Calculated U.S. eczema prevalence estimate using CDC/NCHS Data Brief 545 (adults, 2026), Data Brief 546 (children, 2026), and U.S. Census Bureau 2024 age composition. cdc.gov/nchs/products/databriefs/db545.htm
- [6]Calculated overall eczema prevalence estimate (~8.8%) using CDC/NCHS Data Brief 545 (adults, 7.7%), Data Brief 546 (children, 12.7%), and U.S. Census Bureau 2024 age composition. cdc.gov/nchs/products/databriefs/db545.htm
- [7]Zirwas M, et al. Burden of Atopic Dermatitis in Patients Initiating Systemic Therapies in the United States. Advances in Therapy. 2025. doi.org/10.1007/s12325-025-03286-5
- [8]Tian J, et al. Global Epidemiology of Atopic Dermatitis: A Comprehensive Systematic Analysis and Modelling Study. British Journal of Dermatology. 2024;190(1):55–61. doi.org/10.1093/bjd/ljad339
- [9]Rome BN, et al. Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US. JAMA Dermatology. 2025;161(6):622–628. doi.org/10.1001/jamadermatol.2025.0669
- [10]National Psoriasis Foundation. Plaque Psoriasis. Medically reviewed April 23, 2026. psoriasis.org/plaque
- [11]Worldwide Prevalence of Atopic Dermatitis in Children Between 2000 and 2021: A Systematic Analysis. Annals of Allergy, Asthma & Immunology. 2025;134(5):603–609.e6. doi.org/10.1016/j.anai.2024.12.005
- [12]Zirwas M, et al. Healthcare Resource Utilization and Economic Burden Across Clinical Phenotypes of Moderate-to-Severe Atopic Dermatitis in United States Dermatology Facilities. Dermatology and Therapy. 2026;16:437–450. Published online November 2025. doi.org/10.1007/s13555-025-01590-0
Our Approach
Queen Skin
A Research-Stage Topical Formulation for Inflammatory Skin Conditions
Queen Skin is AriaNova Bio's herbal-based topical formulation being investigated for inflammatory skin conditions, including psoriasis and eczema. Historical case observations and emerging scientific interest have motivated further evaluation of its potential to support skin barrier function and modulate inflammatory responses.
Interested in the Queen Skin Program?
Connect with the AriaNova Bio team to learn more about the Queen Skin program, product development, and potential research or partnership opportunities.